Wells Fargo initiated coverage on Inotiv with a new price target
$NOTV
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2024 | $11.50 → $3.75 | Buy → Hold | Jefferies |
| 2/9/2024 | $3.00 → $11.50 | Hold → Buy | Jefferies |
| 7/20/2023 | $9.00 | Overweight | Wells Fargo |
| 1/19/2023 | $10.00 → $8.00 | Buy → Hold | Jefferies |
| 1/11/2023 | $4.00 → $10.00 | Hold → Buy | Lake Street |
| 11/18/2022 | $60.00 → $7.00 | Buy → Hold | Lake Street |
| 10/4/2022 | $27.00 | Buy | Jefferies |
| 1/31/2022 | $60.00 | Buy | Lake Street |
Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti
WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic
Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously
Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously
Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
SC 13D/A - Inotiv, Inc. (0000720154) (Subject)
EFFECT - Inotiv, Inc. (0000720154) (Filer)
S-3 - Inotiv, Inc. (0000720154) (Filer)
8-K - Inotiv, Inc. (0000720154) (Filer)
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-267-6316 (Domestic)1-203-518-9783 (In
— Third quarter fiscal 2024 revenue down 32.8% to $105.8 million — Year-to-date fiscal 2024 revenue down 16.5% to $360.3 million — Conclusion of certain government investigations — Site optimization projects complete — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q3 FY 2024") and nine months ("YTD FY 2024") ended June 30, 2024. Revenue by Segment (in millions
WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-225-9448 (Domestic)1-203-518-9708 (International)
Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates: Hillcrest, U.K. expansion project completed Extension of the maturity date of the $3.7 million OBRC payable note to July 2025 Robert Leasure Jr., President and Chief Executive Officer, commented, "We have substantially completed the Hillcrest, U.K. expansion and improvements, which allows for two new customers with long term contracts, to begin occupying their new space at this facility and for the transfer
Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12% to $9.05. The company's market cap stands at $269.2 million. RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 7.53% to $4.28. The market value of their outstanding shares is at $149.3 million. Gritstone Bio (NASDAQ:GRTS) shares increased by 7.24% to $0.79. The market value of their outstanding shares is at $85.4 million. Scholar Rock Holding (NASDAQ:SRRK) shares rose 6.96% to $10.14. The company's market cap stands at $808.7 million. Novo Integrated
- Reuters
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
4 - Inotiv, Inc. (0000720154) (Issuer)
WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 138 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. Over the last five years Inotiv grew 847%. Inotiv's president and chief executive officer, Robert Leasure, Jr., credits the company's growth trajectory to listening to customers' concerns and needs. He said, "Inotiv is incredibly proud to be recognized as a 2024 Deloitte Technology Fast 500™ winner for a second year. As we continue to build a top-tier, mid-sized, full-service CRO and provider of research models, we
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-267-6316 (Domestic)1-203-518-9783 (In
WEST LAFAYETTE, Ind., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, will present at the upcoming Jefferies London Global Healthcare Conference. Beth Taylor, Chief Financial Officer, will participate at the upcoming 15th Annual Craig-Hallum Alpha Select Conference. Conference Details Jefferies 2024 London Global Healthcare ConferencePresenter: Robert Leasure Jr., President and Chief Executiv